Supplements Part Of The Past As Perrigo Frames Future Around Rejecting Mylan Tender

The OTC private label leader says its supplement business will be the first asset it sells as it begins a streamlining process, which also includes supply chain consolidation and staff reductions, aimed at $35m in annual cost savings.